Information from Industry- Sponsored Content
The Importance of Guideline-Recommended Biomarker Testing and Multidisciplinary Treatment in Resectable Stage IB-IIIA Non-Small Cell Lung Cancer
Developed under the direction and sponsorship of AstraZeneca
October 5, 2021|CHEST Physician
In this article, Gerard A. Silvestri, MD, MS, FCCP discusses guideline-recommended testing and multidisciplinary care for resectable non-small cell lung cancer.
Neither the editors of CHEST Physician® nor the Editorial Advisory Board nor the reporting staff contributed to this content.
,